- Home
- CRBP vs SPCE Comparison
CRBP vs SPCE Comparison
Compare CRBP & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRBP | SPCE |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 207.3M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRBP | SPCE |
|---|---|---|
| Price | $8.38 | $2.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | ★ $46.17 | $9.22 |
| AVG Volume (30 Days) | 145.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,822,272.00 | ★ $7,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $220.00 | $2,528.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | 3.47 |
| 52 Week Low | $4.64 | $2.18 |
| 52 Week High | $20.56 | $5.59 |
Technical Indicators
Market Signals| Indicator | CRBP | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 45.46 |
| Support Level | $8.39 | $2.37 |
| Resistance Level | $8.43 | $3.42 |
| Average True Range (ATR) | 0.48 | 0.13 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 79.61 | 55.13 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.